Targeted immunotherapy for non-small cell lung cancer.
Publication/Presentation Date
5-10-2014
Abstract
Targeted therapies that deliver the expected anti-tumor effects while mitigating the adverse effects are taking the cancer world by storm. The need for such therapies in non-small cell lung cancer (NSCLC), where systemic cytotoxic chemotherapies still remain the backbone of management, is felt more than ever before. Runway success of immunotherapies such as Ipilimumab for melanoma has brought excitement among oncologists. Immune-based treatments are in various stages of evaluation for NSCLC as well. Immunotherapies using strategies of antigen based or cell based vaccines, and blocking immune checkpoints are of substantial interest. Meaningful clinical responses are yet to be reaped from these new treatment modalities.
Volume
5
Issue
2
First Page
39
Last Page
47
ISSN
2218-4333
Published In/Presented At
Vasekar, M., Liu, X., Zheng, H., & Belani, C. P. (2014). Targeted immunotherapy for non-small cell lung cancer. World journal of clinical oncology, 5(2), 39–47. https://doi.org/10.5306/wjco.v5.i2.39
Disciplines
Medicine and Health Sciences
PubMedID
24829850
Department(s)
Department of Medicine, Hematology-Medical Oncology Division
Document Type
Article